Cargando…
P936: TIME TO RESPONSE, DURATION OF RESPONSE, AND PATIENT-REPORTED OUTCOMES WITH DARATUMUMAB PLUS RD VS RD ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NDMM: SUBGROUP ANALYSIS OF THE PHASE 3 MAIA STUDY
| Autores principales: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431303/ http://dx.doi.org/10.1097/01.HS9.0000846612.13339.9e |
| _version_ | 1784780017162518528 |
|---|---|
| author | Facon, T. Kumar, S. K. Plesner, T. Moreau, P. Bahlis, N. Goldschmidt, H. O’Dwyer, M. Perrot, A. Venner, C. P. Weisel, K. Mace, J. R. Raje, N. Tiab, M. Macro, M. Frenzel, L. Leleu, X. Pei, H. Borgsten, F. Usmani, S. Z. |
| author_facet | Facon, T. Kumar, S. K. Plesner, T. Moreau, P. Bahlis, N. Goldschmidt, H. O’Dwyer, M. Perrot, A. Venner, C. P. Weisel, K. Mace, J. R. Raje, N. Tiab, M. Macro, M. Frenzel, L. Leleu, X. Pei, H. Borgsten, F. Usmani, S. Z. |
| author_sort | Facon, T. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9431303 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94313032022-08-31 P936: TIME TO RESPONSE, DURATION OF RESPONSE, AND PATIENT-REPORTED OUTCOMES WITH DARATUMUMAB PLUS RD VS RD ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NDMM: SUBGROUP ANALYSIS OF THE PHASE 3 MAIA STUDY Facon, T. Kumar, S. K. Plesner, T. Moreau, P. Bahlis, N. Goldschmidt, H. O’Dwyer, M. Perrot, A. Venner, C. P. Weisel, K. Mace, J. R. Raje, N. Tiab, M. Macro, M. Frenzel, L. Leleu, X. Pei, H. Borgsten, F. Usmani, S. Z. Hemasphere Posters Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9431303/ http://dx.doi.org/10.1097/01.HS9.0000846612.13339.9e Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Facon, T. Kumar, S. K. Plesner, T. Moreau, P. Bahlis, N. Goldschmidt, H. O’Dwyer, M. Perrot, A. Venner, C. P. Weisel, K. Mace, J. R. Raje, N. Tiab, M. Macro, M. Frenzel, L. Leleu, X. Pei, H. Borgsten, F. Usmani, S. Z. P936: TIME TO RESPONSE, DURATION OF RESPONSE, AND PATIENT-REPORTED OUTCOMES WITH DARATUMUMAB PLUS RD VS RD ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NDMM: SUBGROUP ANALYSIS OF THE PHASE 3 MAIA STUDY |
| title | P936: TIME TO RESPONSE, DURATION OF RESPONSE, AND PATIENT-REPORTED OUTCOMES WITH DARATUMUMAB PLUS RD VS RD ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NDMM: SUBGROUP ANALYSIS OF THE PHASE 3 MAIA STUDY |
| title_full | P936: TIME TO RESPONSE, DURATION OF RESPONSE, AND PATIENT-REPORTED OUTCOMES WITH DARATUMUMAB PLUS RD VS RD ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NDMM: SUBGROUP ANALYSIS OF THE PHASE 3 MAIA STUDY |
| title_fullStr | P936: TIME TO RESPONSE, DURATION OF RESPONSE, AND PATIENT-REPORTED OUTCOMES WITH DARATUMUMAB PLUS RD VS RD ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NDMM: SUBGROUP ANALYSIS OF THE PHASE 3 MAIA STUDY |
| title_full_unstemmed | P936: TIME TO RESPONSE, DURATION OF RESPONSE, AND PATIENT-REPORTED OUTCOMES WITH DARATUMUMAB PLUS RD VS RD ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NDMM: SUBGROUP ANALYSIS OF THE PHASE 3 MAIA STUDY |
| title_short | P936: TIME TO RESPONSE, DURATION OF RESPONSE, AND PATIENT-REPORTED OUTCOMES WITH DARATUMUMAB PLUS RD VS RD ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NDMM: SUBGROUP ANALYSIS OF THE PHASE 3 MAIA STUDY |
| title_sort | p936: time to response, duration of response, and patient-reported outcomes with daratumumab plus rd vs rd alone in transplant-ineligible patients with ndmm: subgroup analysis of the phase 3 maia study |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431303/ http://dx.doi.org/10.1097/01.HS9.0000846612.13339.9e |
| work_keys_str_mv | AT facont p936timetoresponsedurationofresponseandpatientreportedoutcomeswithdaratumumabplusrdvsrdaloneintransplantineligiblepatientswithndmmsubgroupanalysisofthephase3maiastudy AT kumarsk p936timetoresponsedurationofresponseandpatientreportedoutcomeswithdaratumumabplusrdvsrdaloneintransplantineligiblepatientswithndmmsubgroupanalysisofthephase3maiastudy AT plesnert p936timetoresponsedurationofresponseandpatientreportedoutcomeswithdaratumumabplusrdvsrdaloneintransplantineligiblepatientswithndmmsubgroupanalysisofthephase3maiastudy AT moreaup p936timetoresponsedurationofresponseandpatientreportedoutcomeswithdaratumumabplusrdvsrdaloneintransplantineligiblepatientswithndmmsubgroupanalysisofthephase3maiastudy AT bahlisn p936timetoresponsedurationofresponseandpatientreportedoutcomeswithdaratumumabplusrdvsrdaloneintransplantineligiblepatientswithndmmsubgroupanalysisofthephase3maiastudy AT goldschmidth p936timetoresponsedurationofresponseandpatientreportedoutcomeswithdaratumumabplusrdvsrdaloneintransplantineligiblepatientswithndmmsubgroupanalysisofthephase3maiastudy AT odwyerm p936timetoresponsedurationofresponseandpatientreportedoutcomeswithdaratumumabplusrdvsrdaloneintransplantineligiblepatientswithndmmsubgroupanalysisofthephase3maiastudy AT perrota p936timetoresponsedurationofresponseandpatientreportedoutcomeswithdaratumumabplusrdvsrdaloneintransplantineligiblepatientswithndmmsubgroupanalysisofthephase3maiastudy AT vennercp p936timetoresponsedurationofresponseandpatientreportedoutcomeswithdaratumumabplusrdvsrdaloneintransplantineligiblepatientswithndmmsubgroupanalysisofthephase3maiastudy AT weiselk p936timetoresponsedurationofresponseandpatientreportedoutcomeswithdaratumumabplusrdvsrdaloneintransplantineligiblepatientswithndmmsubgroupanalysisofthephase3maiastudy AT macejr p936timetoresponsedurationofresponseandpatientreportedoutcomeswithdaratumumabplusrdvsrdaloneintransplantineligiblepatientswithndmmsubgroupanalysisofthephase3maiastudy AT rajen p936timetoresponsedurationofresponseandpatientreportedoutcomeswithdaratumumabplusrdvsrdaloneintransplantineligiblepatientswithndmmsubgroupanalysisofthephase3maiastudy AT tiabm p936timetoresponsedurationofresponseandpatientreportedoutcomeswithdaratumumabplusrdvsrdaloneintransplantineligiblepatientswithndmmsubgroupanalysisofthephase3maiastudy AT macrom p936timetoresponsedurationofresponseandpatientreportedoutcomeswithdaratumumabplusrdvsrdaloneintransplantineligiblepatientswithndmmsubgroupanalysisofthephase3maiastudy AT frenzell p936timetoresponsedurationofresponseandpatientreportedoutcomeswithdaratumumabplusrdvsrdaloneintransplantineligiblepatientswithndmmsubgroupanalysisofthephase3maiastudy AT leleux p936timetoresponsedurationofresponseandpatientreportedoutcomeswithdaratumumabplusrdvsrdaloneintransplantineligiblepatientswithndmmsubgroupanalysisofthephase3maiastudy AT peih p936timetoresponsedurationofresponseandpatientreportedoutcomeswithdaratumumabplusrdvsrdaloneintransplantineligiblepatientswithndmmsubgroupanalysisofthephase3maiastudy AT borgstenf p936timetoresponsedurationofresponseandpatientreportedoutcomeswithdaratumumabplusrdvsrdaloneintransplantineligiblepatientswithndmmsubgroupanalysisofthephase3maiastudy AT usmanisz p936timetoresponsedurationofresponseandpatientreportedoutcomeswithdaratumumabplusrdvsrdaloneintransplantineligiblepatientswithndmmsubgroupanalysisofthephase3maiastudy |